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ABSTRACT
Introduction: Neuroblastoma, the commonest paediatric extra-cranial tumour, remains a leading cause
of death from cancer in children. There is an urgent need to develop new drugs to improve cure rates
and reduce long-term toxicity and to incorporate molecularly targeted therapies into treatment. Many
potential drugs are becoming available, but have to be prioritised for clinical trials due to the relatively
small numbers of patients.
Areas covered: The current drug development model has been slow, associated with significant
attrition, and few new drugs have been developed for neuroblastoma. The Neuroblastoma New Drug
Development Strategy (NDDS) has: 1) established a group with expertise in drug development; 2)
prioritised targets and drugs according to tumour biology (target expression, dependency, pre-clinical
data; potential combinations; biomarkers), identifying as priority targets ALK, MEK, CDK4/6, MDM2,
MYCN (druggable by BET bromodomain, aurora kinase, mTORC1/2) BIRC5 and checkpoint kinase 1; 3)
promoted clinical trials with target-prioritised drugs. Drugs showing activity can be rapidly transitioned
via parallel randomised trials into front-line studies.
Expert opinion: The Neuroblastoma NDDS is based on the premise that optimal drug development is
reliant on knowledge of tumour biology and prioritisation. This approach will accelerate neuroblastoma
drug development and other poor prognosis childhood malignancies.
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1. Introduction: the unmet need
Neuroblastoma, the most common extra-cranial solid tumor of
childhood, is a leading cause of death in children between 1
and 4 years [1]. More than 40% of patients are considered high-
risk, including children over the age of 18 months with meta-
static disease and those with tumors harboring MYCN amplifi-
cation [2]. Despite improvements in intensive multimodal
therapy, including chemotherapy, high-dose therapy with auto-
logous hematopoietic stem cell rescue, surgical removal of the
primary tumor, radiotherapy, residual disease therapy, and
immunotherapy with anti-GD2 monoclonal antibodies, long-
term survival for children with high-risk neuroblastoma remains
below 50% at 5 years [3–6]. The majority of patients experience
relapse associated with a dismal prognosis, with 5-year overall
survival for relapsed metastatic neuroblastoma of 8% in the
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International Neuroblastoma Risk Group analysis [7].
Approximately, one third of patients are refractory to frontline
therapy and have a very poor outcome [8,9]. In addition, survi-
vors face a significant burden of late effects due to the intensity
of multimodal therapy [10,11].
2. Current pediatric oncology drug development
model for neuroblastoma
Although genomic aberrations (MYCN, ALK, TP53, ATRX, TERT,
and RAS-MAPK) [12–23], which are molecular drivers for spe-
cific subtypes of neuroblastoma, have been described, effec-
tive molecularly targeted therapies have not been introduced
into current treatment strategies [24]. Furthermore, currently
all children with high-risk neuroblastoma receive the same
therapeutic approach at presentation and treatment is only
modified depending on response – therapy is not persona-
lized. To date, in contrast to adult oncology, progress in
pediatric cancers has been slow, with a paucity of molecularly
targeted drugs being developed for neuroblastoma.
The availability of drugs for early phase clinical studies for
neuroblastoma has been driven predominantly by medicines
being developed for adult malignancies. Although the number
of early phase clinical trials has increased as a result of the
European Paediatric Medicine Regulation, the development of
drugs for neuroblastoma is still driven by the adult condition
and not the mechanism of action of the drug.
After determining the dose and safety profile in a Phase I
study, drugs have been evaluated in Phase II studies with no
clear prioritization to identify those with the greatest potential
benefit for frontline randomized trials. Furthermore, there has
been a lack of comprehensive molecular profiling of tumors at
presentation or relapse. Finally, there has been no integrated
process or a forum for communication and information
exchange between biologists and clinicians involved in early
and phase clinical trials [25].
This fragmented process has resulted in some drugs being
developed with not necessarily the highest biological rationale;
multiple Phase II studies of the samedrug andwith the exception
of anti-GD2 monoclonal antibodies, no new drugs entered front-
line studies for nearly two decades. New therapeutic strategies
are therefore needed for these children [24,26,27].
3. Neuroblastoma New Drug Development Strategy
(NDDS)
The Innovative Therapies for Children with Cancer (ITCC), in
conjunction with the European Network for Cancer Research
in Children and Adolescents (ENCCA) and the International
Society of Paediatric Oncology Europe Neuroblastoma Group
(SIOPEN), has established the Neuroblastoma NDDS project as
part of the overall NDDS initiative developed by ITCC and
ENCCA. The aim is to accelerate the development of new
drugs for patients with neuroblastoma with the ultimate goal
of improving survival.
The neuroblastoma NDDS strategy was designed to encom-
pass all elements of the drug development process, including
translational medicine from bench to bedside: molecular pro-
filing to identify new targets and potential predictive (selec-
tion) biomarkers, development of relevant drugs, biological
and preclinical research, first-in-child early phase clinical stu-
dies, randomized multi-arm trials, and the transition to late-
phase trials and the clinic. Central to the approach was the
premise that optimal drug development is heavily reliant on
understanding tumor biology.
The process was based on the premise that involvement of
all stakeholders was critical for delivering an integrated system
for drug evaluation and clinical trial methodology in children
with neuroblastoma. In view of the large number of potential
targets and drugs becoming available for evaluation in chil-
dren with neuroblastoma, on the one hand, and the genetic
heterogeneity of neuroblastoma with few recurrently altered
genes on the other, a selection and prioritization process was
required to identify targets and drugs which may be of poten-
tial benefit to such children.
This neuroblastoma NDDS is a dynamic process, which prior-
itizes targets and compounds as new data become available.
European experts in neuroblastoma biology and preclinical and
clinical drug development from 15 research institutions in 7
countries are involved, and members of the European
Medicines Agency (EMA) and its Paediatric Committee (PDCO)
are observers.
This output of the NDDS (prioritization and an integrated
approach for drug development in neuroblastoma) informs
clinicians designing early and late phase clinical studies, high-
lights targets and drugs of greatest interest to the pharma-
ceutical industry and regulators, and indicates where
resources require the greatest attention from academia and
industry. This information would be provided for clinical trials
groups and companies preparing pediatric investigation plans
for new drugs. This NDDS strategy complements that of the
multi-stakeholder pediatric platform ACCELERATE, developed
by the Cancer Drug Development Forum (CDDF), ITCC, and
the European Society for Paediatric Oncology (SIOPE) [26], and
with representatives from academia, the pharmaceutical
industry, regulators, and, very importantly, patient representa-
tives. ACCELERATE has developed a process of mechanism of
action and biology-driven selection and prioritization of pedia-
tric drug development, rather than the current process based
on adult cancer indications [28]. This process determines, for
drugs with a known mechanism of action, if that mechanism is
relevant for pediatric malignancy and what is the best match
Article highlights
● The NDDS Project has initiated collaboration between clinicians,
scientists and regulators
● The aim is to accelerate drug development for neuroblastoma
● Targets for neuroblastoma are prioritised according to tumour biology
● Prioritised targets include ALK, MEK, CDK4/6, MDM2, MYCN (drug-
gable by BET bromodomain, aurora kinase and mTORC1/2 inhibition),
BIRC5 and checkpoint Kinase 1
● Drugs targeting these pathways should be prioritized for early clinical
trials
● Drugs that show promise in early phase trials should be evaluated in
parallel randomized or multi-arm, multi-stage studies, and then into
front-line studies - a three stage process from first in child studies to
front-line therapy.
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with tumor biology. The NDDS initiative refines this prioritiza-
tion further within neuroblastoma.
4. Biology of neuroblastoma
Therapeutic targeting of identified oncogenic drivers in neu-
roblastoma is a key component of the NDDS. The first pivotal
step is to identify the molecular pathways and the tumor
biology that are critical drivers in neuroblastoma, focusing
on gene/pathway aberrations with proof of ‘tumor depen-
dence’. Information on the incidence of actionable mutations
is the most easily obtained data for understanding tumor
biology; however, determining the functional dependency of
the mutation, if it is an oncogenic driver or whether it drives
tumor development or recurrence is a more complicated next
stage. Next-generation sequencing has demonstrated that
neuroblastoma harbor fewer mutations involving recurrently
altered genes at diagnosis (mean 10–15 per tumor) than many
other, especially adult, tumors [29]. The main oncogenic dri-
vers identified in neuroblastoma include: (i) MYCN amplifica-
tion in 25% of patients [12]; (ii) anaplastic lymphoma kinase
(ALK) mutations and amplification in 10–15% of cases, includ-
ing those of hereditary neuroblastoma [13–16]; (iii) TP53, wild-
type in the majority of neuroblastoma at diagnosis, with about
2% mutation at presentation, but mutations are acquired dur-
ing treatment and 15% detected at relapse [17]; (iv) RAS-
mitogen-activated protein kinase (MAPK) pathway mutations
recently described in relapsed neuroblastoma (3% mutations
at diagnosis and 78% at relapse) [21]; (v) mutations in ATRX
(9%) reported in older patients [18]; (vi) TERT rearrangements
reflecting telomerase activation in approximately 30% of high-
risk cases [19,20]; and finally (vii) PTPN11 mutations in 2.9% of
tumors [22].
The presence of MYCN amplification, its biological role, and
prognostic relevance were described several decades ago [12].
However, no effective therapeutic strategy demonstrating con-
vincing evidence of MYCN inhibition has yet been translated into
the clinic. After incorporating all biological information available
to date, a recent classification of five groups of drugs targeting
MYC orMYCN at different levels has been reported and will allow
prioritization and development of these agents [30]. The five
groups of drugs comprise drugs targeting: DNA-binding func-
tions of MYCN, transcription of MYCN, synthetic–lethal interac-
tions of MYCN, oncogenic stabilization of MYCN protein, and the
expression or function of MYCN.
ALK was described in 2008 as an oncogenic driver in neu-
roblastoma [13–16] and an early clinical trial of crizotinib in
children with ALK aberrations was rapidly initiated [31].
However, resistance to single-therapy agent crizotinib has
been described preclinically and clinically with moderate
response rates (1 complete response, 3 stable disease, and 7
progressive disease of 11 ALK mutated neuroblastoma) in
early clinical trials compared to other ALK-driven tumors [32].
Hence, both combinations with chemotherapy or other tar-
geted agents or more potent inhibitors are needed to over-
come resistance of some ALK mutations [33].
The tumor suppressor protein p53 is usually nuclear and
wild-type at diagnosis (98% of tumors) in neuroblastoma,
with intact apoptotic mechanisms, although aberrations in
the p53/MDM2/p14ARF pathway are more commonly
reported. Interestingly, the p53 gene TP53 is a direct tran-
scriptional target of MYCN and sensitizes cells for MYCN-
driven apoptosis [34,35].
The appearance of activating mutations of the RAS/MAPK
pathway has also been recently described in a high proportion
of neuroblastoma at relapse (up to 78%); some of them are
novel whereas others are clonally enriched at relapse [21].
Emerging data highlight the importance of other targets
such as the cell cycle regulator CDK4/6 [36,37].
ATRX gene mutations/focal deletions are mutually exclu-
sive with MYCN amplification and occur in 9% of high-risk
patients at diagnosis [22]. ATRX mutations/deletions are also
strongly associated with the alternative lengthening of the
telomeres phenotype [18,38]. The clinical features of this
group include older age at diagnosis, a chronic progressive
course, and poor long-term overall survival [18]. However,
to date, no novel therapies exist for this important target. In
2015, genomic rearrangements proximal to TERT, which
encodes the catalytic subunit of the telomerase enzyme,
resulting in its transcriptional upregulation, were described
in 23–31% of high-risk cases [19,20]. TERT rearrangements
are also associated with poor prognosis and occur in a
mutually exclusive fashion to MYCN amplification and ATRX
alterations. Taken together with evidence that MYCN also
upregulates TERT, these recent discoveries highlight the
importance of active telomere maintenance in neuroblas-
toma pathogenesis and present a new potential therapeutic
target [19].
Molecular profiling of tumor tissues bio-banked at the
time of diagnosis has yielded important data, as reported
in recent whole exome sequencing (WES)/whole genome
sequencing (WGS) publications [22,23]. The European ITCC
initiatives are providing data with the aim of discovering
novel therapeutics for high-risk disease by routinely mole-
cularly profiling tumors at relapse (MOlecular Screening for
CAncer Treatment Optimisation (MOSCATO-01) [39],
MoleculAr Profiling for Pediatric and Young Adult Cancer
Treatment Stratification (MAPPYACTS), Individualized
Therapy for Relapsed Malignancies in Childhood (INFORM)
[40], Individualised Therapy (iTHER), and Stratified Medicine
– Paediatrics (SM-PAEDS), as is the Therapeutically
Applicable Research to Generate Effective Treatments
(TARGET) project in the US, which analyses both primary
and relapsed neuroblastoma [41,42]. More recently, the
appearance of new mutations in individual patients at
the time of relapse has been demonstrated for ALK, TP53,
and RAS/MAPK [17,21,43–45]. As has been described for
other cancers, these mutations are detected at low levels
in diagnostic samples but are enriched at relapse and
several of these are potentially important drug targets.
Understanding the evolution of mutations in neuroblas-
toma is of critical importance for drug development
[21,43–45]. It underlines that re-biopsying tumors at the
time of relapse and obtaining snap-frozen tumor and par-
affin-embedded material before entering early clinical trials
is increasingly important and should be incorporated into
clinical practice. This will provide accurate molecular pro-
filing of neuroblastoma and facilitate access to novel
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targeted therapies through a personalized medicine
approach, as well as improving our understanding of dis-
ease biology and mechanisms of resistance to new, tar-
geted therapies. The importance of clonal evolution in
neuroblastoma has made it necessary to study sequential
samples collected during targeted therapy to understand
mechanisms of resistance. As sequential tumor sampling
may not be feasible, the role of liquid samples has become
more important. Emerging technologies allow the detec-
tion of actionable mutations in circulating DNA obtained
from blood samples, as has been recently shown with the
detection of ALK mutations in plasma samples [46].
5. Incorporation of biological data: the transition
from preclinical to clinical development –
prioritization of targets in neuroblastoma
A number of articles and workshop reports have been pub-
lished without achieving a definitive consensus defining the
minimal data package required to provide proof-of-concept
and therefore to qualify a target or drug as sufficiently promis-
ing to take forward into clinical trials for adult cancers [47–49].
For pediatric cancers, the first step should be to prioritize the
targets according to the level of existing evidence, then define
whether there are available drugs for the target, and finally
establish if they are available for pediatric use and whether
early phase clinical trials of these agents should be prioritized.
Targets were preselected for evaluation based on the cur-
rently available data at that time on molecular pathology,
biology, and preclinical studies. The decisions to prioritize
targets for clinical development were taken by a consensus
of clinicians, scientists, and academic drug development
experts based on specific criteria, which included the robust-
ness of the published evidence that they were oncogenic
drivers, the functional dependence in neuroblastoma, and
whether they were strong candidates for druggable targets.
Targets were ranked as ‘high’ (n = 9), ‘intermediate’ (n = 5), or
‘low’ (n = 7) to enable prioritization based on target expression,
target dependency and validation, availability of preclinical data
on efficacy, and potential combination and biomarker develop-
ment. The targets that were given top priority for neuroblastoma
based on the available data, completeness of the data, and
potentially available inhibitors were ALK, MEK, CDK4/6, MDM2,
MYCN (druggable by BET bromodomain, aurora kinase, and
mTORC1/2 inhibition), BIRC5, and checkpoint Kinase 1 [50,51].
TORC1/2 aurora kinase and BET bromodomain were ranked as
high-priority targets because of their action on MYCN; however,
it was agreed that currently no aurora kinase inhibitor exhibits
optimal activity against MYCN [52–54]. LIN28B [55] was identified
as an important target, but currently no drugs are in develop-
ment. Table 1 summarizes the data available for each target and
Table 2 the clinical development of relevant drugs. For all these,
the target is expressed in neuroblastoma, has been validated in
vitro and/or in vivo with siRNA functional experiments, and
shows strong evidence of efficacy in vitro and in vivo. Research
to identify biomarkers, combinations, or resistance is less well
developed, but nevertheless for these targets it was felt that
there was sufficient data to guide initial clinical development.
The evidence to date suggests that some of these targets are
only relevant to molecular subpopulations, for example, ALK for
ALKmutated or amplified neuroblastoma. For other agents such
as mTORC1/2, aurora kinase, or CHK1 inhibitors, evidence sug-
gests that they will be active in MYCN-driven neuroblastoma, but
they could also have a role in non-MYCN-driven tumors.
The critical importance of combinations has been highlighted,
as these may enhance efficacy in the majority of instances where
dysregulation of more than one biological pathway is responsible
for driving the disease and overcome resistance. However, the
mechanism of action and cumulative toxicities of additional
agents must be carefully considered when designing treatment
regimens. A substantial logistical challenge lies in the systematic
evaluation of the numerous possible permutations of combina-
tions in a clinical setting [56]. In view of the limited number of
children available for early phase studies, a rational approach is
needed for the selection of combinations based on the biology of
neuroblastoma and its known biological subsets as well as path-
ways’ data in tumors treated with one agent involved in the
combination. Following preclinical evaluation of the combinations
in a range of well-characterized models derived from patients’
tumors or genetically engineered models, a proposed combina-
tion should be evaluated clinically. The study of genomic and
pharmacodynamic biomarkers during the clinical evaluation will
exemplify a ‘from the bench to the bedside and back again’
approach. Finally, there must be an awareness of unexpected or
greater toxicities with these combinations and extrapolation from
adult experience is essential.
6. Drugs relevant to prioritized targets
Pediatric early phase clinical trials are ongoing or have
recently closed for ALK and aurora kinase inhibitors [31,57–63].
For neuroblastoma, the responses seen with crizotinib are
disappointing and are substantially lower than those seen
with tumors driven by ALK translocations – inflammatory
myofibroblastic tumor, anaplastic large cell lymphoma, and
non-small cell lung cancer [31]. The challenge then is to
identify more potent drugs or combinations which can over-
come the inherent resistant of ALK mutations in neuroblas-
toma. Currently, three ALK inhibitors are marketed for the
treatment of ALK-driven non-small cell lung cancer (crizotinib,
ceritinib, and alectinib) and three more are in development in
adults (brigatinib, lorlatinib, and entrectinib). Pediatric trials of
single agents ceritinib (LDK378) and entrectinib as well as
combinations of ALK inhibitors with mTOR or CDK4/6 inhibi-
tors are ongoing [61–63] and preclinical data relating to lorla-
tinib are encouraging and a Phase I trial has been activated for
ethical/IRB approval [64–66]. The optimal ALK inhibitor for
neuroblastoma has yet to be determined clinically, but once
identified will be evaluated in frontline studies.
Aurora kinase inhibitors are cytotoxic in their own right, as
well as acting on the MYCN–aurora complex. Two aurora kinase
inhibitors, alisertib and AT9283, have been evaluated in Phase I
studies in children with neuroblastoma [58–60]: AT9283 as a
single agent and alisertib as a single agent and in combination
with irinotecan and temozolomide. Activity has been observed
with alisertib both as single agent and in combination.
However, activity of alisertib was lowest in MYCN-amplified
neuroblastoma suggesting that its mechanism of action was
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by a cytotoxic effect rather than on the MYCN–aurora complex.
This further supports the hypothesis that the optimal aurora
kinase inhibitor, eliciting conformational changes on the
MYCN–aurora complex, has yet to be developed [52–54].
Although mTOR inhibitors – everolimus, temsirolimus, and
ridaforolimus [67–71] – have been evaluated in clinical trials in
children, pediatric trials of the new mTORC1/2 inhibitors have
just opened and are a high priority for the pediatric academic
community because the dual mTORC1/2 inhibition could over-
come resistance to rapalogues.
The first-in-child trial of the CDK4/6 inhibitor ribociclib
(LEE011) has been recently completed [72], with stable disease
a frequent outcome, demonstrating the importance of a com-
bination approach, and trials of abemaciclib (LY2835219) and
palbociclib are ongoing [73,74]. Early pediatric clinical trials of
the MEK inhibitors selumetinib, trametinib, and cobimetinib
and the pan phosphatidylinositol 3-kinase (PI3K) inhibitor
SF1126 [75] are in progress. Additionally, MDM2, BIRC5, CHK1,
and BET bromodomain inhibitors are in the early clinical phases
of adult development, but pediatric clinical trials have not yet
started. Although there is a strong biological mechanism of
action rationale for such development of these inhibitors, the
slowness in opening early phase pediatric studies reflects that
pediatric drug development is still largely centered on adult
conditions and not the mechanism of action-based model [28].
7. Transition to clinical development: considerations
for early and late clinical trials
Based on the foundation of the neuroblastoma NDDS, there
are four elements for clinical evaluation of new drugs: early
phase clinical trials, parallel randomized later phase clinical
trials, molecular profiling, and randomized frontline trials.
Central to the overall approach is the seamless transition
between evaluation of a new drug for a particular molecular
subtype by the Clinical Trials Committee of ITCC and evalua-
tion specifically for relapsed neuroblastoma by the Drug
Development Group of SIOPEN.
The objective of an early phase clinical trial is not only to
determine the pediatric-recommended Phase II dose (RP2D),
safety profile, pharmacokinetics, and pharmacodynamics of a
drug, but also to assess preliminary signals of activity. As the
pediatric RP2D remains very close to the equivalent adult
RP2D and toxicity profiles are class-related and similar to
adult drugs [76], for drugs with a wide therapeutic index, it
is recommended that the pediatric early phase clinical trial
starts at the adult RP2D, corrected for body surface area, and is
a dose confirmation study. Using this approach [76], pharma-
cokinetic profiling is critical and the exposures, clearances, and
other pharmacokinetic parameters can be confirmed to be
similar to those obtained in adults as well as the toxicity
profile. Conversely, if the drug has a narrow therapeutic
index, then a dose escalation study is required. Existing dose
escalation designs such as 3 + 3 were developed for evaluat-
ing chemotherapeutics. For molecularly targeted agents, the
use of these conventional dose escalation designs leads to
longer study durations, studies remaining closed to recruit-
ment for long periods, and more dose levels being tested [77].
New dose escalation designs, such as the Bayesian logistic
regression model (BLRM) or continuous reassessment method
(CRM), maximize the efficiency of the dose escalation by lead-
ing to a shorter duration of trials and less exposure of patients
to doses below the maximum tolerated dose (MTD) [78].
The inclusion of patients with the same molecular subtype or
disease in early phase trials of expansion cohorts will enable a
valuable assessment of activity, as well as providing further data
on safety and pharmacokinetics. Relatively small-sized expansion
cohorts can inform statistically go/no-go decisions; for example,
an Ensign 3-stage design [79], where 10 patients are recruited at
the RP2D, as used in the European Proof-of-Concept Therapeutic
Stratification Trial of Molecular Anomalies in Relapsed or
Refractory Tumours (ESMART) trial (NCT02813135) [80]. If there
is no response in the first 10 patients, then a further evaluation of
the drug is postponed or abandoned. However, if there is a
response in the first 10 patients, then a further 16 patients are
enrolled. Also, the recently presented pediatric study on the
BRAF inhibitor dabrafenib included four expansion cohorts with
10 patients each, providing statistically based estimations to
guide go/no-go decisions [81,82].
If there is preliminary evidence of activity, then the drug is
evaluated further in neuroblastoma-specific, adaptive-design, par-
allel, randomized or multi-arm, multistage studies. Evaluation in
randomized trials is essential, as a comparison with historical
controls will overestimate the efficacy of the drug [83].
Finally and importantly, molecular profiling of the patient’s
tumor at the time of enrolment on an early phase clinical trial is
a critical component of the strategy. Due to clonal evolution and
tumor heterogeneity, evaluation of archival tumor is not appro-
priate. ‘Liquid biopsies’ of circulating free DNA are increasingly
being incorporated in both early and randomized trials and will
give sequential information about tumor evolution and develop-
ment of resistance. European ITCC initiatives are providing this
information by routine molecular profiling of tumors at relapse
(MOSCATO-01 [39], MAPPYACTS, INFORM [40], iTHER, SM-PAEDS).
Currently, the multi-pharma, multi-drug ITCC early phase clin-
ical trial ESMART (NCT02813135) [78] (which includes NDDS
prioritized drugs – mTORC1/2, and CDK4/6 inhibitors) and the
randomized SIOPEN – ITCC BEACON trial [84] – provide a clear
pathway for the evaluation of drugs identified in the NDDS to go
forward to frontline studies. Single agents or combinations,
which show activity in the randomized trial, are then introduced
into frontline therapy and evaluated further – a three-stage
process from first-in-child studies to frontline therapy.
By utilizing this approach, pediatric dose confirmation/finding
studies can be conducted rapidly, and activity can be determined
more quickly, with meaningful comparators and biological
knowledge gained in parallel with prospective molecular
profiling.
8. Conclusions and action points
The NDDS initiative, created by ITCC, ENNCA, and SIOPEN,
aims to accelerate drug development by bringing together
biologists, drug developers, regulators, and clinicians leading
early and late phase trials, to achieve a consensus. Drug
development for neuroblastoma must be driven by biology
and knowledge of the molecular pathways, tumor biology,
and key oncogenic drivers. Targets have been prioritized
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based on biology, specifically target expression, target depen-
dency and validation, and preclinical data on efficacy, poten-
tial combinations, and availability of biomarkers. Since the
start of the NDDS initiative, ITCC and SIOPEN have increased
efforts to accelerate the development of the prioritized inhi-
bitors. Furthermore, there is a clear continuum incorporating
molecular profiling, biological and preclinical data, mechanism
of action-driven strategy for selection and prioritization, and
improved early and late phase clinical trial design to stream-
line the drug development process (Table 3). A closer dialog
with the pharmaceutical industry will further increase the
efficiency of this plan, as will the introduction of a mechanism
of action and biology-driven selection and prioritization pro-
cess in pediatric drug development. This approach will guide
scientists, clinicians, pharmaceutical industry, and regulators in
the immediate future and will enable access to the most
promising targeted agents in the hope of improving outcomes
for children with neuroblastoma, and potentially other child-
hood malignancies.
9. Expert opinion
The existing model of drug development for neuroblastoma is
generally reactive and responds to drugs being developed for
adult malignancies. Furthermore, in the past there has not
been integration and coordination between early and late
phase clinical studies. Drug development is not driven by
the biology of the tumor and the known genomic drivers.
This process results in drugs being evaluated that may not
have the greatest probability of activity in neuroblastoma, and
their course of development is interrupted and not planned,
and frequently trials compete for small populations. Increased
collaboration and data sharing between all stakeholders is
needed to avoid regulators and pharma not being aware of
developments, and lacking an overview of the landscape of
the disease, therapeutic needs, and new scientific discoveries.
The approach adopted by the NDDS initiative is integrated,
comprehensive, and based on tumor biology, and results in a
more efficient and rational process and use of valuable and rare
resources. The neuroblastoma NDDS encompasses all elements
of the drug development process, including translational med-
icine from bench to bedside: molecular profiling to identify new
targets and potential predictive (selection) biomarkers, relevant
drugs, biological and preclinical research, first-in-child early
phase clinical studies, randomized multi-arm trials, and the
transition to late-phase trials and to frontline standard of care.
Central to the approach is the premise that optimal drug
development is reliant on understanding tumor biology.
Selection of drugs should be driven by the aberrant molecular
pathways in neuroblastoma [28]. The biological hypotheses
relevant to each drug should be tested in the clinic through
the use of omic and pharmacodynamic ancillary biomarker
Table 3. Summary of NDDS strategy.
Molecular profiling ● Molecular profiling at diagnosis and at the time of relapse is highly encouraged
Preclinical data evaluation should comprise (adapted
depending on specifics of each target)
● Target status in clinical series
● Target validation (tumor dependence of the target)
● In vitro activity
● In vivo activity
● Biomarkers (pharmacodynamic and predictive)
● Information about resistance mechanisms and how to overcome those
● Data on the rational combinations
Prioritization of targets and drugs ● ALK, MEK, CDK4/6, MDM2, BET bromodomain, aurora kinase, mTORC1/2, BIRC5, and checkpoint
Kinase 1 given top priority for pursuing in early clinical trials
Population for early clinical trials in neuroblastoma should
include
● Patients showing early progressive disease
● Refractory patients after induction and second-line chemotherapy (INRC2 criteria)
● Patients with early relapse – during therapy and ≤1 year after diagnosis
● Patients with late relapses – 1 year after diagnosis. Relapses >1 year after diagnosis have longer
progression-free survival, although survival is still extremely poor and so new therapies should be
offered
Mechanism of action biology-driven drug development ● Goal is to match the biology of tumors with existing drugs (with known mechanism of action) as
early as possible in the drug development process
● Strategy for selection and prioritization of potential pediatric indications rather than the current
process based on adult cancer indications.
Early phase clinical trial designs ● Early phase clinical trials should incorporate expansion cohorts in the tumor of interest to obtain
proof-of-concept
● Start at 100% of the adult body surface area adjusted equivalent RP2D, with attention paid to very
young children with immature organs
● Bayesian or continuous reassessment method dose escalation design should be used
● It is necessary to incorporate biomarkers into early clinical trials in order to accelerate and improve
the efficiency of the drug development process by molecular preselection
Parallel randomized trials ● Single arm Phase II studies should be abandoned
● Randomized parallel trials should be performed based on molecular preselection
● More efficient adaptive Phase II designs should be incorporated (Bayesian, pick-the-winner, drop-
the-loser, octopus, multi-arm multistage [MAMS]).
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studies. This approach is in contrast to the present model,
where drug selection is dictated by the adult indication and
not necessarily by the probability that the medicine will have
the greatest patient benefit in childhood tumors. The major
challenge of the proposed model is the availability of drugs.
This could be increased by including re-prioritization of drugs
developed for adults, which may not be of high priority for
adult cancers, or by incentivizing the development of drugs
specifically for pediatric cancers. Once this proposed model is
incorporated, its results will need to be evaluated prospectively
to finally demonstrate that it was fit for purpose and has
speeded up drug development for childhood cancers.
A critical feature of the NDDS initiative is bringing together
experts in neuroblastoma biology and preclinical and clinical
drug development and leaders of late-phase studies, with
regulators as observers. In this way information can be shared,
all participants have a common knowledge, and decisions can
be made collectively.
The neuroblastoma NDDS has delivered three outputs:-
(1) A multidisciplinary expert group has been established,
with participants involved in all aspects of the drug
development process, which is able to have a dynamic
overview of all new targets and drugs available for the
disease.
(2) Targets have been prioritized based on target valida-
tion and completeness of nonclinical data, including
available inhibitors, combinations, resistance mechan-
isms, and biomarkers: ALK, MEK, CDK4/6, MDM2, MYCN
(BET, Aurora kinase, and mTORC1/2), BIRC5, and CHK1
inhibitors. The process is dynamic, and new targets and
drugs are regularly reviewed.
(3) Clinical trials of the prioritized targets and drugs have
been promoted by liaising with pharma and facilitating
investigator-led trials through ITCC.
This output of the NDDS greatly assists clinicians designing early-
and late-phase clinical studies and the pharmaceutical industry
and regulators who are made aware of targets and drugs of
greatest interest. Scientific advice can be sought from regulators
at early stages in development. Resources from academia and
industry can be directed to areas with greatest potential yield.
As neuroblastoma has different genomic drivers, with clo-
nal evolution and tumor heterogeneity, molecular character-
ization with a precision medicine approach will be critical. The
ultimate goal is a therapeutic approach comprising: molecular
profiling tumor categorization, molecular targeted therapy for
‘known’ genomic drivers, and a strategy for biologically rele-
vant cancer vulnerabilities. We believe this novel approach will
accelerate neuroblastoma drug development and should be
applied to other poor prognosis childhood malignancies.
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